Skip to main content
main-content

05.12.2016 | Original Article | Ausgabe 4/2017

International Journal of Hematology 4/2017

BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma

Zeitschrift:
International Journal of Hematology > Ausgabe 4/2017
Autoren:
Shoko Nishizawa, Mamiko Sakata-Yanagimoto, Keiichiro Hattori, Hideharu Muto, Tran Nguyen, Koji Izutsu, Kenichi Yoshida, Seishi Ogawa, Naoya Nakamura, Shigeru Chiba
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s12185-016-2159-z) contains supplementary material, which is available to authorized users.

Abstract

BCL6, a master transcription factor for differentiation of follicular helper T (TFH) cells, is highly expressed in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphomas (PTCL) containing tumor cells with TFH features. TET2, encoding an epigenetic regulator, is frequently mutated in AITL/PTCL. We previously reported that Tet2 knockdown mice developed T-cell lymphomas with TFH features. Hypermethylation of the Bcl6 locus followed by BCL6 upregulation was thought to be the key event for lymphoma development in mice. The mechanisms by which BCL6 expression is upregulated in human AITL/PTCL, however, have not been elucidated. Here, we investigated the impact of TET2 mutations on methylation of BCL6 locus in human AITL/PTCL samples. Hypermethylation of the BCL6 locus was more frequent in PTCL samples than B-cell lymphoma samples (PTCL vs B-cell lymphomas: 9/42 vs 0/35). PTCL samples with TET2 mutations were more frequently hypermethylated than those without TET2 mutations (PTCL with TET2 mutations vs without mutations: 6/22 vs 0/17). BCL6 expression in hypermethylated samples was higher than that in low methylated samples. Deregulated BCL6 expression caused by hypermethylation and TET2 mutations may result in skewed TFH differentiation and eventually contribute to AITL/PTCL development in patients, as well as lymphoma development in Tet2 knockdown mice.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (PPTX 149 kb)
12185_2016_2159_MOESM1_ESM.pptx
Supplementary material 2 (PPTX 149 kb)
12185_2016_2159_MOESM2_ESM.pptx
Supplementary material 3 (PPTX 85 kb)
12185_2016_2159_MOESM3_ESM.pptx
Supplementary material 4 (XLS 34 kb)
12185_2016_2159_MOESM4_ESM.xls
Supplementary material 5 (XLS 32 kb)
12185_2016_2159_MOESM5_ESM.xls
Supplementary material 6 (XLSX 11 kb)
12185_2016_2159_MOESM6_ESM.xlsx
Supplementary material 7 (XLS 32 kb)
12185_2016_2159_MOESM7_ESM.xls
Supplementary material 8 (XLS 33 kb)
12185_2016_2159_MOESM8_ESM.xls
Supplementary material 9 (XLS 42 kb)
12185_2016_2159_MOESM9_ESM.xls
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2017

International Journal of Hematology 4/2017Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  3. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise